Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSPO | P30536 | 1/20 | 0.68 |
| ▸ | CBX7 | O95931 | 6/20 | 0.58 |
| ▸ | CDYL2 | Q8N8U2 | 6/20 | 0.58 |
| ▸ | CDYL | Q9Y232 | 6/20 | 0.58 |
| ▸ | CDY1; CDY1B | Q9Y6F8 | 4/20 | 0.58 |
| ▸ | KMO | O15229 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25865036 | 0.86 | TSPO (0.53) | TSPO | |
| SCHEMBL14426217 | 0.86 | TSPO (0.59) | TSPO | |
| SCHEMBL25869117 | 0.85 | TSPO (0.52) | TSPOCBX7CDYL2CDYLCDY1; CDY1B | |
| SCHEMBL25868351 | 0.85 | TSPO (0.52) | TSPO | |
| SCHEMBL29957877 | 0.79 | KMO (0.76) | TSPOCBX7CDYL2CDYLCDY1; CDY1B | |
| SCHEMBL2950965 | 0.79 | KMO (0.76) | TSPOCBX7CDYL2CDYLCDY1; CDY1B | |
| SCHEMBL29958210 | 0.78 | CDYL2 (0.69) | TSPOCBX7CDYL2CDYLCDY1; CDY1B | |
| SCHEMBL27033393 | 0.78 | CDYL2 (0.69) | TSPOCBX7CDYL2CDYLCDY1; CDY1B | |
| SCHEMBL25864993 | 0.77 | MEN1 (0.54) | TSPOKMOTP53MAPTSMN1; SMN2 | |
| SCHEMBL30538038 | 0.76 | CBX7 (0.60) | CBX7CDYL2CDYLCDY1; CDY1BTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219938-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PREC MEDICINES INC (US) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219938-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | TSPO 394/4885CBX7 1133/4885CDYL2 1702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.